Organic compounds -- part of the class 532-570 series – Organic compounds – Sulfur containing
Reexamination Certificate
2008-05-20
2008-05-20
Padmanabhan, Sreenvasan (Department: 1616)
Organic compounds -- part of the class 532-570 series
Organic compounds
Sulfur containing
C514S712000, C568S049000, C568S050000, C568S051000, C568S052000
Reexamination Certificate
active
07375252
ABSTRACT:
This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
REFERENCES:
patent: 3179701 (1965-04-01), Rocklin
patent: 4029812 (1977-06-01), Wagner et al.
patent: 4076841 (1978-02-01), Wagner et al.
patent: 4078084 (1978-03-01), Wagner et al.
patent: 4115590 (1978-09-01), Lerner
patent: 4752616 (1988-06-01), Hall et al.
patent: 4755524 (1988-07-01), Mueller et al.
patent: 4954514 (1990-09-01), Kita et al.
patent: 4968710 (1990-11-01), Rustad
patent: 4975467 (1990-12-01), Ku et al.
patent: 5043330 (1991-08-01), Nguyen et al.
patent: 5061734 (1991-10-01), Mao et al.
patent: 5066822 (1991-11-01), Rustad
patent: 5084214 (1992-01-01), Kita et al.
patent: 5112870 (1992-05-01), Mao et al.
patent: 5206247 (1993-04-01), Regnier et al.
patent: 5262439 (1993-11-01), Parthasarathy
patent: 5294724 (1994-03-01), Jendralla et al.
patent: 5310949 (1994-05-01), Dufresne et al.
patent: 5411741 (1995-05-01), Zaias
patent: 5426196 (1995-06-01), Fang
patent: 5608095 (1997-03-01), Parker et al.
patent: 5627205 (1997-05-01), Regnier et al.
patent: 5693337 (1997-12-01), Suzuki et al.
patent: 5739374 (1998-04-01), Janssen et al.
patent: 5770355 (1998-06-01), Brocia
patent: 6037377 (2000-03-01), Anderskewitz et al.
patent: 6121319 (2000-09-01), Somers
patent: 27 16 125 A 1 (1977-10-01), None
patent: 0 190 682 (1986-08-01), None
patent: 0 212 310 (1987-03-01), None
patent: 0 254 272 (1988-01-01), None
patent: 0 292 660 (1988-11-01), None
patent: 0 317 165 (1989-05-01), None
patent: 0 348 203 (1989-12-01), None
patent: 0 405 788 (1991-01-01), None
patent: 0 621 255 (1994-10-01), None
patent: 0 763 527 (1997-03-01), None
patent: 0 866 049 (1998-09-01), None
patent: 2.130.975 (1972-11-01), None
patent: 2.133.024 (1972-11-01), None
patent: 2.134.810 (1972-12-01), None
patent: 2.140.769 (1973-01-01), None
patent: 2.168.137 (1973-08-01), None
patent: 1136539 (1968-12-01), None
patent: 1148550 (1969-04-01), None
patent: 1199871 (1970-07-01), None
patent: 73-28425 (1995-12-01), None
patent: 93/02051 (1993-02-01), None
patent: 94/07869 (1994-04-01), None
patent: 95/09158 (1995-04-01), None
patent: 95/15760 (1995-06-01), None
patent: 95/17408 (1995-06-01), None
patent: 95/30415 (1995-11-01), None
patent: 96/12703 (1996-05-01), None
patent: 97/15546 (1997-05-01), None
patent: 97/26258 (1997-07-01), None
patent: 97/48694 (1997-12-01), None
patent: 98/22418 (1998-05-01), None
patent: 98/30255 (1998-07-01), None
patent: 98/42327 (1998-10-01), None
patent: 99/15159 (1999-04-01), None
patent: 99/24400 (1999-05-01), None
patent: 00/26167 (2000-05-01), None
patent: 00/26184 (2000-05-01), None
patent: 00/31053 (2000-06-01), None
patent: 00/53795 (2000-09-01), None
patent: 00/59509 (2000-10-01), None
Theodora W. Greene and Peter G.M. Wuts, Protective Groups in Organic Synthesis, 3rdedition, 1999, pp. 231-232.
Barnhart, J.W., et al., The Synthesis, Metabolism, and Biological Activity of Probucol and its Analogs,Pharmacochem. Libr. No. 17, (1991), pp. 277-299.
BioCentury Extra (The Bernstein Report of BioBusiness), “AtheroGenics: Faster than Anticipated,” (Reprint from May 29, 2001).
Chemical Abstracts Service, Columbus, Ohio, US; STN,Chemical Abstracts, 28-Heterocyclic Compounds (More Than One Hetero Atom), vol. 124, No. 1, 1996, p. 921.
Chemical Abstracts Service, Columbus, Ohio, US; STN,Chemical Abstracts, 28-Heterocyclic Compounds (More Than One Hetero Atom), vol. 124, No. 11, 1996, p. 1251.
Cominacini et al., Antioxidants Inhibit the Expression of Intercellular Cell Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Induced by Oxidized LDL on Human Umbilical Vein Endothelial Cells,Free Radical Biology&Medicine, vol. 22, Nos. 1/2, pp. 117-127, 1997.
DeMeglio, P. et al., Farmaco, Ed. Sci., 40(11), 833-844 (1985) (partial English language translation).
Feldman et al., The in vitro and ex vivo antioxidant properties, and hypolipidemic activity of CGP 2881,Atherosclerosis, vol. 144, No. 2 (Jun. 1999), pp. 343-355.
Press Release, Nov. 12, 2001, “AtheroGenics Announces Positive Phase II Results From CART-1 Clinical Trial for Restenosis”.
Fruebis et al., A Comparison of the Antiatherogenic Effects of Probucol and of a Structural Analogue of Probucol in Low Density Lipoprotein Receptor-deficient Rabbits,J. Clin. Invest., vol. 94, Jul. 1994, pp. 392-398.
Gershbein et al., Ation of Drugs and Chemical Agents on Rat Liver Regeneration,Drug and Cheical Toxicology, 8(3), 125-143 (1985).
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 122:187387J, see abstract, Kobayashi et al., vol. 122, 1995.
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 94:30290c, see abstract, Mamedov et al., vol. 94, 1981.
Mao et al., Attenuation of Atherosclerosis in a Modified Strain of Hypercholesterolemic Watanabe Rabbits With Use of a Probucol Analogue (MDL 29,311) That Does Not Lower Serum Cholesterol,Arteriosclerosis and Thrombosis, vol. 11, No. 4, Jul/Aug. 1991.
Mao et al., Antioxidant Activty of Probucol and Its Analogues in Hypercholesterolemic Watanabe Rabbits,Journal of Medicinal Chemistry, 1991, vol. 34, pp. 298-302.
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 86:5066m, see abstract: Medvedev et al., vol. 86, 1997, p. 437.
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 1970:445047, XP002124423; see abstract; Neuworth et al.,J. Med. Chem., (1970), vol. 13, No. 4, 722-725.
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 110:212254a, see abstract; Pastor et al., vol. 110, 1989.
Ramasamy et al., Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxdant in Cultured Endothelial Cells,Modlecular Pharmacology, vol. 56, No. 1, Jul. 1999, pp. 116-123.
Roberts et al., Regulation of monocyte to macrophage differentiation by antiglucocorticoids and antioxidants,American Journal of Obstetrics and Gynecology, vol. 179, No. 2, Aug. 1998, pp. 354-362.
Chemical Abstracts Service, Columbus, Ohio, US; STN, see abstract; Tomich et al., vol. 127, No. 6, 1997.
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 126:277465v, see abstract; Toshiaki et al., vol. 126, No. 21, 1997, p. 669.
Chemical Abstracts Service, Columbus, Ohio, US; STN, accession No. 86189w, see abstract; Wagner, Jr., et al., vol. 82, 1975.
AtheroGenics, Inc.
King & Spalding
Padmanabhan Sreenvasan
Schlientz Nathan W.
LandOfFree
Compounds and method for the inhibition of the expression of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and method for the inhibition of the expression of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and method for the inhibition of the expression of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2797718